Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Fox Corp Class B — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.73 (market cap $29.60B), while Fox Corp Class B trades at $55.3 (market cap $24.58B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Fox Corp Class B pays a 1.05% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FOX | |
|---|---|---|
Market Cap | $29.60B | $24.58B |
Sector | Health | Media |
52-Week High | $491.22 | $67.76 |
52-Week Low | $205.48 | $44.39 |
Enterprise Value | $27.56B | $27.94B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
FOX trades at $56.33, down 1.23% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent earnings beats and strong 2025 results, including $16.3B revenue and $2.26B net income, support a P/E of 14.41. Positive news includes Tubi's partnership with Gracenote for CTV advertising growth (PRNewswire, Aug 12, 2026).
The outlook is positive with robust ad momentum and digital expansion, though risks include cyclical advertising exposure and high RSI suggesting near-term pullback potential. Analyst consensus leans neutral with 42.86% buy ratings, indicating cautious optimism for long-term holders amid competitive media pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
